Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

@article{Wilcken2008ChemotherapyIM,
  title={Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.},
  author={N. Wilcken and Rachel F Dear},
  journal={European journal of cancer},
  year={2008},
  volume={44 15},
  pages={
          2218-25
        }
}
  • N. Wilcken, Rachel F Dear
  • Published 2008
  • Medicine
  • European journal of cancer
    • AIM To summarise the findings of all randomised trials comparing chemotherapy regimens for metastatic breast cancer that were reported between 2000 and 2007 inclusive. METHODS We searched the specialised register of clinical trials maintained by the secretariat of the Cochrane Breast Cancer Group (CBCG) from 2000 to 2007, and abstracts from the American Society of Clinical Oncology (ASCO) annual scientific meeting (2000-2007). RESULTS Eighty reports of 63 trials were identified as eligible… CONTINUE READING
    View on PubMed
    doi.org
    57 Citations
    Highly Influential Citations
    2
    Background Citations
    21
    Methods Citations
    2
    Results Citations
    2
    57 Citations
    Citation Type

    Citation Type

    In the end what matters most? A review of clinical endpoints in advanced breast cancer.
    • 59
    Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome
    • 13
    An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval
    • 4
    Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
    • E. D. Saad, A. Katz, M. Buyse
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 132
    Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006
    • 11
    • PDF
    Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectoscope.
    • 2
    Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.
    • 94
    • PDF
    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
    • 78
    Survival of de novo stage IV breast cancer patients over three decades
    • 19
    Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy
    • 6

    References

    SHOWING 1-10 OF 61 REFERENCES
    Single agent versus combination chemotherapy for metastatic breast cancer.
    • 190
    A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC)
    • 14
    Platinum containing regimens for metastatic breast cancer.
    • 55
    Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
    • 23
    Antitumour antibiotic containing regimens for metastatic breast cancer.
    • 25
    Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences.
    • 48
    Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
    • E. Winer, D. Berry, +14 authors L. Norton
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 194
    Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
    • 173
    Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
    • 16
    Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.
    • 141